FastNeoTM

FastNeoTM deliver a robust ex-vivo screen using state-of-the-art engineered APCs to be able to obtain 70% Asian population coverage (HLA-I and HLA-II). This validation tool provide higher sensitivity (up to 30%) and rapid screen (7 days).

SCIENTIFIC PROBES:
1 submitted paper

1 patent filed to USPTO